Sarepta Therapeutics, Inc.
SRPT
$19.05
-$0.08-0.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 64.99% | 10.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 64.99% | 10.91% | |||
| Cost of Revenue | -83.56% | 95.86% | |||
| Gross Profit | 317.62% | -1,046.79% | |||
| SG&A Expenses | -15.08% | 39.62% | |||
| Depreciation & Amortization | 2.07% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -56.35% | 84.54% | |||
| Operating Income | 187.40% | -552.18% | |||
| Income Before Tax | 223.31% | -43.42% | |||
| Income Tax Expenses | 168.40% | 132.27% | |||
| Earnings from Continuing Operations | 217.01% | -57.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 217.01% | -57.18% | |||
| EBIT | 187.40% | -552.18% | |||
| EBITDA | 191.16% | -811.19% | |||
| EPS Basic | 216.79% | -50.35% | |||
| Normalized Basic EPS | 181.19% | -533.53% | |||
| EPS Diluted | 206.48% | -50.14% | |||
| Normalized Diluted EPS | 169.92% | -533.53% | |||
| Average Basic Shares Outstanding | 0.19% | 4.55% | |||
| Average Diluted Shares Outstanding | 16.34% | 4.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||